Tampilkan postingan dengan label prices. Tampilkan semua postingan
Tampilkan postingan dengan label prices. Tampilkan semua postingan

Jumat, 01 September 2017

$475,000 is a good deal for Kymriah, and a bad sign for controlling health care costs

$475,000 is a good deal for Kymriah, and a bad sign for controlling health care costs

Today's Managing Health Care Costs Number is $475,000

Personalized medicine is here - and it's a miracle.  Novartis' newly-approved drug Kymriah is genetically engineered immune cells from the patient which will kill leukemia cells, and it's shown remarkable efficacy in small trials.  One girl was dying of leukemia five years ago and remains in remission, and gave stirring testimony for the drug's approval before the FDA last month. (Photo of Emily Whitehead, above, is from the Associated Press via the NY Times)

This is just the beginning - training one's own immune cells to fight cancer (and possibly other diseases) holds enormous promise.  The cost: $475,000 for the one-time treatment.

Here are the reasons we shouldn't worry about that eye-popping cost

  • $475,000 is a small price to pay for a cure of an otherwise fatal disease- especially in a kid.  With a life expectancy of 70 years, this could mean the cost per Quality Adjusted  Life Year (QALY) is under $7000.
  • The drug has been approved for a rare cancer- with under 60 people likely to be eligible each year.  If all of them responded and paid full price, that's under $30 million.   Putting this in perspective, this is 0.0008% of national health care expenditures.
  • Novartis will restrict use to just 30-35 centers, so we won't have unqualified physicians prescribing this willy-nillly.  The engineered cells can cause life-threatening reactions - so this is an important safety measure
  • Novartis has promised refunds if there is no response in 1 month, and has also promised financial assistance for families without insurance coverage

You can probably guess that I'm worried, though.

Kymriah is the first of a set of CAR-T therapies - and there are a gaggle more on the way.  Some of them will be used for much more common conditions, and even Kymriah is likely to be used much more widely than the FDA-approved indications.   Gilead Pharmaceuticals just paid $11 billion for Kite, a cancer therapy company that has a CAR-T therapy tailored to non-Hodgkins Lymphoma expected to be approved in the next year.  The cost is likely to be similar, and the market larger. The total cost for CAR-T therapies will likely rise to many billions in just a few years.

Novartis has broken yet another price ceiling -and this will make it easier for the prices of other oncology medicines to continue to rise.   See this post for how this works with Multiple Sclerosis drugs.

Refunds for non-efficacy sound good in theory - but are often ineffective in practice.  This research showed "such schemes have poorly contributed to the fulfillment of the purpose in Italy, producing a trifling refund."

Financial assistance programs have largely been focused on maintaining price discipline - and have helped contribute to pharmaceutical company bottom lines by increasing revenue from other payers and offering the pharmas favorable tax treatment.

These genetically engineered cells will never be produced by a generic company - and are unlikely even to be produced as biosimilars for a long time if ever.   So if very high prices "stick," we should expect to pay them for the foreseeable future.

We should celebrate - this is an enormous feat of American medicine.  The initial research was performed at the University of Pennsylvania - but this drug would never had made it to market without the investment, trials, and regulatory work done by Novartis.

But we need to address drug prices if we are to control health care costs, and the high price set for Kymriah  is a bad omen.

Rabu, 29 Maret 2017

New EpiPen alternative for $4500!


Today’s Managing Health Care Costs Number is $4500



It seems like eons ago that we were arguing over EpiPen – an autoinjector that delivers a dirt-cheap generic medication that can save the life of someone who has an allergic reaction.  The drug was purchased by Mylan pharmaceuticals which progressively raised its price from $100 to $750 – and faced massive public outcry. 

Mylan’s CEO (the daughter of WV Senator Joe Manchin (D)) was subjected to Congressional hearings, and the company lowered the price (from $750 to $600) and introduced a generic version for half the price (which undersold another generic)

One interesting sidenote was that there had been an EpiPen competitor, Auvi-Q, produced by Sanofi, which gave audio instructions for injection. This had been priced competitivelywith EpiPen when it was introduced in 2013 (each was a bit shy of $250 for two doses) - but had been removed from the market due to production issues.

Good news.  Auvi-Q is back!

Not so good news.  Auvi-Q is priced at $4500 for two doses.

WHAT? 

It’s getting hard to summon outrage about pharmaceutical prices (and a lot else).  Why should a delivery system that was priced at $250 in 2013 be marketed for $4500 in 2017?  Obviously, when it comes to pricing there is no shame – the company selling this also sells Evzio, an autoinjector for naloxone  to reverse narcotic overdose for $4500

EpiPen Google searches 


Kamis, 02 Februari 2017

Can Trump Put a Lid on Pharma Prices?

Can Trump Put a Lid on Pharma Prices?


Today's Managing Health Care Costs Number is $325 billion

We have a drug price crisis in the United States.  Total cost of pharmaceuticals is now 1/5 of costs for many employers, and we routinely see new drugs priced at $100,000.   Some of these drugs are lifechanging (like new treatments for melanoma and hepatitis C cures), although others are only marginal improvement over existing less expensive therapy (many other cancer drugs).  Last year drug spending climbed 9% to $325 billion; it climbed 12% the previous year. Source 

Donald Trump has promised to unleash the market by slashing regulations on drug companies, but has threatened to tame drug prices through competitive bidding and his bully pulpit. 

Let's look at the underlying causes of high drug costs to consider what is likely to happen during the Trump administration.

  1. Innovation:   When a company produces a product that meets a real need - there is value to that - and the company will general price its product to reflect its value to purchasers.
  2. Chronic disease: Our population is getting older and we have more obesity and diabetes - so the prevalence of chronic disease is up. The pharmas have been effective at producing drugs that address chronic disease - so "customer retention" is high - and lifetime cost of a chronic medication is almost always more than for acute self-limited treatment .
  3. Government policy: The US is the only high income country that doesn't employ either price regulation or monopsony purchasing to keep pharma prices in check.  Pharmaceutical companies raise prices because they can
  4. Supply chain:  The supply chain in pharmacy is a mess.   The pharmaceutical companies sell to wholesalers who provide drugs to local pharmacies; pharmacy benefit managers (PBMs) negotiate prices on behalf of employers with the pharmaceutical company.  "List" prices are irrelevant - rebates are paid form the pharmaceutical company to the PBM in an utterly opaque manner - so determining the true price paid for a drug is maddeningly difficult.
  5. Moral hazard:   Insurers have employed cost sharing as a way to encourage patients as consumers to purchase drugs prudently.  But the pharmas provide coupons and even give drugs away to avoid lowering their "list" price, and fund dedicated charities to decrease patient cost share again to protect their price
  6. Social norms:  CEOs want their companies to be successful, and given mostly fixed costs of producing any given drug, price increases are the best way to gain higher margin
     

The Trump administration's proposals to decrease FDA regulation are not likely to decrease the cost of drugs.  The FDA is pretty quick with its reviews at this point - and regulatory issues are not the main development cost.   If we allow marketing of medicines with unproven efficacy that will likely increase cost - as they will all have a price tag, and some won't work and some might even be harmful.  The use of rebates and coupons makes it unlikely that patients will be able to be true "value" purchasers.

There appears to be no chance the FDA will initiate review of cost effectiveness of pharmaceutical products at this point. The FDA could allow importation of a drug from other "trusted" countries when there was a shortage or when a medication was viewed to be priced too high in the US - and this could help keep a lid on prices. This will be less effective for single source brand name drugs, where the manufacturer could limit supply to other countries where the price is lower.

Some regulation of the supply chain with full disclosure of rebates could make a difference - although that's regulation we're unlikely to see.  I also think we're unlikely to see Medicare Part D amended to allow CMS to do bulk price negotiation.  This works well for the Veteran's Administration -but that would be increasing the government role, which I see is unlikely.

Which brings us to bully pulpit.   Pharmaceutical companies (just like health plans or hospital systems) are sensitive to their public image -and they don't want to be subjects of Donald Trump's angry early morning tweets.   I think the invective around drug prices is likely to have some impact, although I worry there will be a few high profile price rollbacks (like Mylan's Epipen) and the overall costs of pharmaceuticals will continue to soar.

Senin, 28 November 2016

It's STILL the prices!


Today’s Managing Health Care Costs Number is 4.6%



It’s still the prices, stupid!  (See this link for previous posts on this topic)

The Health Care Cost Institute published its third annual compendium of health care costs for employer sponsored health insuranceduring Thanksgiving week, and total costs of providing medical coverage for the employer sponsored population went up by 4.6% - more than in the previous two years that HCCI has evaluated. 

Price growth (as opposed to utilization growth) continued to drive the total cost of care. Inpatient utilization declined by almost 4% (but prices went up by over 6% -which more than wiped out any potential savings.  Prescription utilization went down very slightly –but price per unit was up 9%, and outpatient and professional utilization went up a bit – but the price increases drove more of the total cost trend.

Primary care problem-focused office visits dropped (they have decreased at an annualized rate of 4.7% since 2012).   However, primary care preventive visits (those annual exams that are not all that useful) went up by 2%. Specialist visits also increased by 2.4%– and there are more visits to specialists than to PCPs. 







The HCCI data continues to show us that our main challenge is cost per unit – as opposed to decreasing utilization.  High deductible health plans have been effective at lowering utilization – but there is little that health plans have been able to do consistently to lower unit prices.    The most promising approaches include:

·      Narrow networks (restricted to high quality providers with lower unit prices)
·      Tiered networks (where patients pay more out of pocket to see the providers with higher unit prices)
·      Transparency tools, which help patients know in advance the price of a provider that they intend to see.  However, the “friction” involved is high – and it’s been a challenge to show that patients effectively use these tools.  (Castlight published one study showing that imaging unit costs were lower for those who used its transparency tool  - although this hasn’t been replicated).
·      Reference pricing –where the insurer covers up to a reference price and all costs beyond that are out of pocket – is only practical for high ticket expenses.

There are a number of third parties which have programs to lower unit cost.   Vitalshas gotten substantial press-  it has worked with a number of states to give patients a share of savings from going to less expensive providers, largely for imaging and for drug infusions.  There are a number of companies that run call centers that promise higher touch and the ability to direct patients to higher value  providers, although these have not published peer reviewed results. Health plans also promise to direct their members to more cost-effective providers.

Most developed countries have national fee schedules –and providers are not allowed to charge what are regarded as excessive fees.   Clearly, this is not likely to be acceptable in the US.

Lower prices are natural in industries with healthy competition (look at the progressive decreases in costs of computers or clothing.)  But lower prices require disruptive innovation –and the health care industry regulations and payment methods encourage accretive innovation that raises costs, even if improvement of quality is miniscule. It’s painful for an industry to accept lower prices –and lower prices can mean substantial cutbacks given fixed costs.  

The hospital industry agreed to decreased Medicare fee increases in part to gain more insured patients as part of the Affordable Care Act, and is already advocating that any repeal include restoring the higher future Medicare rate increases.